Using the CMAP database, we used 19 hub immune genes (KMT2A, PTPN1, TFAP2C, TLR7, SMARCE1, KLRD1, LIFR, FZD1, FST, TGFB2, KLRC4, CYSLTR1, PIK3R1, BCAR1, TRIM36, CCR9, THBS1, NOD2, and C7) to forecast latent therapeutic medicines for CRSWNP. The gene discussed is FST; the disease is chronic rhinosinusitis with nasal polyps.